Patent · US Active

CD73 inhibitors

US11028074B2 · kind B2 · utility

0Cited by
1References
22Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 22, 2019
Grant dateJun 8, 2021
Priority date
Expiry dateFeb 22, 2039

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

The present invention provides 5-[5]-[2-cycloalkyl]-6-pyridazin-3-yl]-1H-pyrimidine-2,4-dione compounds, or pharmaceutically acceptable salts thereof, that inhibit the activity of CD73 and are useful in treating cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.